NCT03823859

Metabolomics of Thyroid Hormones

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 332 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to develop a metabolome signature of thyroid hormone status. The metabolome signature could be useful in diagnosis and treatment of thyroid dysfunction diseases, especially in cases where TSH cannot be reliably used.

Detailed description

Primary Hypothyroidism is a frequent endocrine disorder, where the thyroid gland does not produce sufficient amounts of thyroid hormones. The substitution therapy is guided by measurement of the pituitary gland hormone thyrotropin (TSH). Patients with central hypothyroidism in whom pituitary insufficiency leads to hypothyroidism, TSH cannot be used to guide therapy. So far there are no reliable methods for therapy control in patients with central hypothyroidism. The measurement of small endogenous metabolites might give investigators a metabolomics profile. This could help to discriminate between euthyroid, hypothyroid and hyperthyroid state and therefore could be used for diagnosis and therapy control of thyroid dysfunction diseases.

Conditions

• Central Hypothyroidism
• Hypothyroidism
• Hyperthyroidism

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Indirect calorimetry	Resting energy expenditure
DIAGNOSTIC_TEST	Dual energy X-ray Absorptiometry (DXA)	Body composition
DIAGNOSTIC_TEST	Blood sampling	fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel

Timeline

• Start date: 2018-12-12
• Primary completion: 2021-07-28
• Completion: 2021-12-31
• First posted: 2019-01-31
• Last updated: 2022-05-17

Locations

1 site across 1 country: Switzerland